Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Blome James	2. Issuer Name and Ticker or Trading Symbol Calyxt, Inc. [ CLXT ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                      _____ 10% Owner __ X __ Officer (give title below)      _____ Other (specify below) Chief Executive Officer
(Last)          (First)          (Middle) 2800 MOUNT RIDGE ROAD	3. Date of Earliest Transaction (MM/DD/YYYY) 6/28/2019
(Street) ROSEVILLE, MN 55113 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	6/28/2019		A		50000   (1)	A	$0	204136	D

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right-to-Buy)	$12.48	6/28/2019		A		125000		6/28/2020   (2)	6/28/2029	Common Stock	125000	$0	125000	D
Performance Stock Units	(3)	6/28/2019		A		166667		(3)	6/28/2022	Common Stock	166667	$0	166667	D

Explanation of Responses:
(1)	50,000 Restricted Stock Units with respect to Calyxt, Inc. common stock were granted to reporting person on 6/28/2019 and vest as to 15% of the underlying shares on the first anniversary of the Grant Date, as to 10% of the underlying shares on the second anniversary of the Grant Date, and as to 5% of the underlying shares on the last day of each calendar quarter beginning on the first full calendar quarter after the second anniversary of the Grant Date.
(2)	Stock Option vests as to 15% of the underlying shares on the first anniversary of the Grant Date, as to 10% of the underlying shares on the second anniversary of the Grant Date, and as to 5% of the underlying shares on the last day of each calendar quarter beginning the first full calendar quarter after the second anniversary of the Grant Date.
(3)	Each performance stock unit (PSU) represents a contingent right to receive one share of Calyxt common stock. The PSU will vest as to 50%, 100% or 120% of the shares at the end of a three year performance period based upon increases in Calyxt common stock from the starting price of $12.48 (and on a linear basis between vesting percentages) and if vested, will be issued as restricted stock with restrictions lapsing on the two year anniversary of the date of issuance.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Blome James 2800 MOUNT RIDGE ROAD ROSEVILLE, MN 55113			Chief Executive Officer

Signatures
Dr. Andre Choulika, Attorney-in-Fact for James Blome		7/2/2019
** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.